特异性单克隆与非特异性多克隆抗体荧光免疫偏振法测定肾移植病人全血环孢素浓度的比较及肝功能对血药浓度的影响

摘要/Abstract

摘要： 目的观察特异性单克隆抗体与非特异性多克隆抗血清荧光免疫偏振法测定肾移植病人全血环孢素浓度的差异及肝功能对血药浓度的影响。方法对36位肾移植术后病人的84份环孢素(CsA)血样同时用特异性单克隆(MAFPIA)和非特异性多克隆抗体(PAFPIA)荧光免疫偏振分析法进行测定。对两种方法测得的数值进行统计学处理。结果 MAFPIA与PAFPIA之间有较好的线性关泉(相关系数为0. 8947),两者的测得值具统计学显著性差异。肝功能异常的患者PAFPIA测得值显著大于MAFPIA测得值。与肝功能正常患者相比有明显差异,且两者的回归曲线参数均有明显不同。结论对 CsA血药浓度测定应采用特异性高的方法。

关键词: 环孢素, 荧光免疫偏振分析法, 肝功能, 血药浓度

Abstract: Aim This study was to investigate the influence of specific and nonspecific detecting methods on CsA blood concentration in renal transplanting patients, and to observe the effects of hepatic function on CsA concentration. Methods Eighty-four whole blood specimens from 36 renal transplant recipients who had received cyclosporine (CsA) were measured with MAFPIA and PAFPIA. Results Linear regression analysis showed that there was a better rela tionship between PAFPIA and MAFPIA (r = 0.8974). Values of PAFPIA in patients with reduced hepatic function was significantly higher than those of MAFPIA. Both regression curve parameters differed greatly from each other. It is suggested that therapeutic drug monitoring for CsA should be performed with the specific method.

Key words: Cyclosporine A, Fluorescence polyriza tion immunoassay, Blood concentration

中图分类号:

R969

王峰, 张华峰, 李颖, 苏士平, 孙斌. 特异性单克隆与非特异性多克隆抗体荧光免疫偏振法测定肾移植病人全血环孢素浓度的比较及肝功能对血药浓度的影响[J]. 中国临床药理学与治疗学, 1996, 1(1): 13-16.

Wang Feng, Zhang Huafeng, Li Ying, Su Shiping, Sun Bin. Determination of cyclosporine A by the fluorescence polar-ization immunoassay methods in renal transplant recipients and the influence of hepatic function on CsA concentration[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 13-16.

参考文献

1 Faulds D, Goa KL Benfield P. Cyclosporin:areview of its pharmacodynamic and pharmacokinetic properties, and therapeulic use in immunoregulatory disorders. Drugs, 1993, 45:953
2 Tjandrea-Maga B, Verbessel R, Scharpe S, e1 al. Comparison of cyclosporin A measurement in whole blood by six different methods. J Clin Chem Clin Biochem, 1990, 28:53
3 Kahan BD,Grevel J. Oplimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation, 1988, 46:631
4 Grevel J, Welsh MS,Kaham BD. Cyclosporine monitoring in renal transplanlation area under the curve monitoring is superior to trough - level monitoring. Ther Drug Monit, 1989, 11:246
5 Mraz W,Muller C,Monlar B,et al. Analysis oJ cyclosporin A (CsA) concentrations by fluorescence po-larization immunoassay (FPIA):comparison with radio immunoassay (RIA) and liquid chromalography (HPLC). Tranplant Proc, 1989,21:885
6 Sanghvi A,Diven WF,Warly VS,et al. Cy-closporine measurement by FPIA utilizing abboll TDx instrumenl. Transplant Proc, 1989, 21:898
7 Napoli KL, Kahan BD. Nonseleclive measuremenl of cyclosporine for therapeulic drug monitoring by fluores-cence polarization immunoassay with a rabbit polyclonal antibody:I. Evaluation of the serum methodology and comparison with a sheep polyclonal antibody in an ³H-trancer mediated radioimmunoassay. Tranplant Proc, 1990, 22:1175
8 Vine W, Bowers LD. Cyclosporine:Structure, phar-macokinetics, and therepeutic drug monitoring. Crit Rev Clin Lab Sci,1987, 25:275
9 Lindholm A. Faclors influencing the pharmacokine1-ics of cyclosporine in man. Ther Drug Monit, 1991, 13:465
10 Lensmeyer GL,Wlebe RA,et al. Distribulion of cyclosporine A melabolites among plasma and cells in whole blood:Effect of temperature, Hemalocrit, and metabolite concentralion. Clin Chem,1989,35:56
11 Yee GC. Recent advances in cyclosporine phnrma-cokinetics. Pharmacotherapy, 1991,11:130s
12 Hartman NR,Jardine l. The in vilro activitv, ra-dioimmunoassay crossreactivity, and molecular weight of thirteen. Drug Metab Dispos, 1987, 15:661
13 Freeman DJ. Pharmacology and pharniacokinetics of cyclosporine. Clin Biochem,1991,24:9

[1]	余巧玲, 翟葳葳, 刘平, 邱博, 吴惠珍. 利伐沙班血药浓度监测的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 809-817.
[2]	柳彤, 徐佳明, 王金伙, 尹磊, 陈永权, 郭建荣. 急性等容血液稀释自体血体外隔离期间血浆中麻醉药物浓度变化及回输后对麻醉效应的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 413-418.
[3]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[4]	胡殷, 杨丹丹, 徐毅超, 邵蓉, 阮邹荣, 江波, 陈金亮, 楼洪刚. 人工神经网络模型在坎地沙坦酯片生物等效性研究中的应用[J]. 中国临床药理学与治疗学, 2022, 27(1): 63-69.
[5]	符祥俊, 黄莉, 郭丽, 林良沫. 万古霉素AUC/MIC在多重耐药革兰阳性菌致重症感染中的应用分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 775-781.
[6]	王晖, 徐晓芳, 李荣. 治疗药物监测在环孢素A个体化给药中的应用及研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 707-713.
[7]	尹磊, 徐佳明, 吴敬医, 段立双, 卫含伟, 金孝岠, 郭建荣. 急性等容血液稀释自体血回输对老年骨科手术患者脑电双谱指数与肌松效应的影响[J]. 中国临床药理学与治疗学, 2021, 26(10): 1153-1158.
[8]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[9]	王高卿, 江伟, 华永飞. 雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 752-756.
[10]	郭明星, 郭恒, 沈素, 孙丽莹, 崔向丽. 肝功能不全患者伏立康唑血药浓度监测回顾性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 757-763.
[11]	孙青, 孙建芳, 李力, 常会超, 周权. 五酯胶囊对大鼠体内辛伐他汀及其代谢物辛伐他汀酸药代动力学影响[J]. 中国临床药理学与治疗学, 2020, 25(11): 1242-1249.
[12]	毛云，张兆瑞. 人参皂苷诱导骨髓间充质干细胞对急性肝功能衰竭大鼠肝组织再生及Wnt/β-catenin信号表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 503-510.
[13]	赵全凤，符佩姝，马欢，赵粟裕，郭代红，唐敏. 伏立康唑所致肝功能损害的主动监测研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 43-48.
[14]	李力，李贺，刘杏娥，魏楠. LC-MS/MS法测定肿瘤患者血浆中阿帕替尼浓度及其临床应用[J]. 中国临床药理学与治疗学, 2018, 23(7): 790-795.
[15]	喻君，金孝岠，郭建荣，鲁美静，曹亚，常燕. 不同血液稀释法对老年肝癌手术患者凝血及肝脏功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(3): 308-312.